Does Age Matter? Estimating Risks of Locoregional Recurrence After Breast-conservative Surgery.
Breast cancer
breast cancer
breast-conservative treatment
elderly
tailored treatment
Journal
In vivo (Athens, Greece)
ISSN: 1791-7549
Titre abrégé: In Vivo
Pays: Greece
ID NLM: 8806809
Informations de publication
Date de publication:
Historique:
received:
20
02
2020
revised:
12
03
2020
accepted:
13
03
2020
entrez:
2
5
2020
pubmed:
2
5
2020
medline:
9
2
2021
Statut:
ppublish
Résumé
In 2016, in the United States, more than 50% of breast cancer (BC) cases were diagnosed in patients older than 60 years of age. Our study aimed to estimate the risk of locoregional recurrence (LR) in patients who underwent breast-conservative treatment (BCT), according to age. This retrospective monocentric study analyzed 613 cases of patients who underwent BCT between 2003 and 2014. Patients were divided into groups according to age: Under70 (under 70 years old) and Over70 (above 70 years old). Margins width, histology results, prognostic and predictive factors were compared. Subgroup analysis was performed for patients who experienced LR. LR Incidence among Under70 and Over70 was 5.4% and 1.7%, respectively (p<0.01). Group Over70 is characterized by larger tumors and a lower Ki67 index (p<0.01). Operation time reduction, better aesthetic results and reduced LR risk support BCT. The Over70 group exhibited better outcomes in terms of LR despite larger tumor dimensions.
Sections du résumé
BACKGROUND/AIM
OBJECTIVE
In 2016, in the United States, more than 50% of breast cancer (BC) cases were diagnosed in patients older than 60 years of age. Our study aimed to estimate the risk of locoregional recurrence (LR) in patients who underwent breast-conservative treatment (BCT), according to age.
PATIENTS AND METHODS
METHODS
This retrospective monocentric study analyzed 613 cases of patients who underwent BCT between 2003 and 2014. Patients were divided into groups according to age: Under70 (under 70 years old) and Over70 (above 70 years old). Margins width, histology results, prognostic and predictive factors were compared. Subgroup analysis was performed for patients who experienced LR.
RESULTS
RESULTS
LR Incidence among Under70 and Over70 was 5.4% and 1.7%, respectively (p<0.01). Group Over70 is characterized by larger tumors and a lower Ki67 index (p<0.01).
CONCLUSION
CONCLUSIONS
Operation time reduction, better aesthetic results and reduced LR risk support BCT. The Over70 group exhibited better outcomes in terms of LR despite larger tumor dimensions.
Identifiants
pubmed: 32354901
pii: 34/3/1125
doi: 10.21873/invivo.11884
pmc: PMC7279857
doi:
Substances chimiques
Biomarkers, Tumor
0
Receptors, Estrogen
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1125-1132Informations de copyright
Copyright© 2020, International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.
Références
Breast J. 2020 May;26(5):1096-1098
pubmed: 31763725
Surg Clin North Am. 2018 Aug;98(4):819-833
pubmed: 30005776
Nature. 2015 Oct 1;526(7571):144
pubmed: 26245370
J Clin Oncol. 2009 May 20;27(15):2466-73
pubmed: 19349544
Int J Mol Sci. 2017 Jul 07;18(7):
pubmed: 28686211
Eur J Cancer Care (Engl). 2010 Mar;19(2):145-66
pubmed: 19674072
Sao Paulo Med J. 2006 May 4;124(3):130-4
pubmed: 17119688
J Clin Oncol. 2016 Nov 20;34(33):4040-4046
pubmed: 27528719
JAMA Surg. 2017 Apr 1;152(4):378-384
pubmed: 28002557
Breast Cancer Res Treat. 2017 May;163(1):119-130
pubmed: 28205042
Am J Surg. 2002 Aug;184(2):89-93
pubmed: 12169349
Eur Rev Med Pharmacol Sci. 2017 Mar;21(6):1341-1345
pubmed: 28387892
Curr Treat Options Oncol. 2015 Apr;16(4):16
pubmed: 25796377
Oncology. 2001;61 Suppl 2:1-13
pubmed: 11694782
Hum Pathol. 1986 Apr;17(4):330-2
pubmed: 3957334
Lancet Oncol. 2015 Mar;16(3):266-73
pubmed: 25637340
In Vivo. 2019 Nov-Dec;33(6):1879-1884
pubmed: 31662515
Surgery. 2019 Oct;166(4):709-714
pubmed: 31395398
Ann Thorac Surg. 2010 Sep;90(3):973-8
pubmed: 20732526
Cancer. 2010 Jun 15;116(12):2913-21
pubmed: 20336782
In Vivo. 2019 Nov-Dec;33(6):1985-1992
pubmed: 31662528
Ig Sanita Pubbl. 2012 Sep-Oct;68(5):657-76
pubmed: 23223317
J Am Coll Surg. 2017 May;224(5):895-905
pubmed: 28238934
J Clin Oncol. 2014 May 10;32(14):1507-15
pubmed: 24516019
N Engl J Med. 2012 Jul 5;367(1):79-82
pubmed: 22762325
Oncology. 2006;71(3-4):176-84
pubmed: 17652942
World J Surg Oncol. 2011 Oct 17;9:131
pubmed: 22004841
J Clin Oncol. 1989 Aug;7(8):1120-8
pubmed: 2569032
N Engl J Med. 2002 Oct 17;347(16):1233-41
pubmed: 12393820
J Med Screen. 2018 Mar;25(1):17-23
pubmed: 28614991
J Reconstr Microsurg. 2017 May;33(4):257-267
pubmed: 28061518
PLoS One. 2017 Sep 18;12(9):e0184680
pubmed: 28922402
J Natl Cancer Inst. 2000 Apr 5;92(7):550-6
pubmed: 10749910
Postepy Hig Med Dosw (Online). 2015 Apr 08;69:447-51
pubmed: 25897105
Breast. 2017 Aug;34 Suppl 1:S82-S84
pubmed: 28673535
J Natl Cancer Inst. 1999 Feb 17;91(4):368-73
pubmed: 10050871
Ann Surg. 1898 Nov;28(5):557-76
pubmed: 17860646
Anticancer Res. 2020 Feb;40(2):939-950
pubmed: 32014938
Health Psychol. 2013 Jun;32(6):695-705
pubmed: 23088176
Nurse Pract Forum. 1999 Sep;10(3):145-53
pubmed: 10614359
Clin Obstet Gynecol. 2016 Dec;59(4):772-778
pubmed: 27681690
Anticancer Res. 2019 Sep;39(9):4941-4945
pubmed: 31519599
Int J Cancer. 2019 Apr 15;144(8):1941-1953
pubmed: 30350310
Cancer. 1985 Sep 1;56(5):979-90
pubmed: 2990668
JAMA. 2018 Sep 25;320(12):1277-1278
pubmed: 30178060
Exp Ther Med. 2010 Sep;1(5):747-754
pubmed: 22993598
Anticancer Res. 2020 Jan;40(1):281-286
pubmed: 31892577
Anticancer Res. 1996 Jul-Aug;16(4B):2187-92
pubmed: 8694541
J Plast Reconstr Aesthet Surg. 2016 Oct;69(10):1325-34
pubmed: 27498596
Eur J Oncol Nurs. 2013 Jun;17(3):311-6
pubmed: 22947216
Lancet Oncol. 2013 Dec;14(13):1269-77
pubmed: 24225155
Eur J Cancer. 2013 Oct;49(15):3093-101
pubmed: 23800672
Future Oncol. 2014 Nov;10(14):2293-301
pubmed: 25471040
J Clin Oncol. 2011 Jul 1;29(19):2610-2
pubmed: 21606411
Breast Cancer Res Treat. 1998 May;49(1):69-78
pubmed: 9694613
Anticancer Res. 2018 Apr;38(4):2109-2117
pubmed: 29599329
Eur J Cancer. 1995 Sep;31A(10):1574-9
pubmed: 7488404
Eur J Cancer. 2005 Nov;41(17):2637-44
pubmed: 16115758
N Engl J Med. 1981 Jul 2;305(1):6-11
pubmed: 7015141
Gland Surg. 2019 Jun;8(3):271-282
pubmed: 31328106
Nat Rev Clin Oncol. 2010 Jun;7(6):348-53
pubmed: 20309006
Cancers (Basel). 2019 Feb 21;11(2):
pubmed: 30795637
Eur Rev Med Pharmacol Sci. 2016 Jul;20(14):2950-4
pubmed: 27460720
In Vivo. 2017 01-02;31(1):101-110
pubmed: 28064227
Gynecol Obstet Fertil Senol. 2019 Nov;47(11):811-815
pubmed: 31493562
Cancer. 2018 Apr 1;124(7):1335-1341
pubmed: 29338088
J Racial Ethn Health Disparities. 2017 Dec;4(6):1181-1188
pubmed: 28004356
Anticancer Res. 2001 May-Jun;21(3C):2091-7
pubmed: 11501831
Lancet. 2005 May 14-20;365(9472):1727-41
pubmed: 15894099
Tumori. 2002 May-Jun;88(3):S48-9
pubmed: 12365390
Eur J Surg Oncol. 2017 Feb;43(2):303-310
pubmed: 28069398
Updates Surg. 2020 Feb 15;:
pubmed: 32062785